Pear Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference
August 31 2022 - 8:00AM
Business Wire
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing
and commercializing software-based medicines called prescription
digital therapeutics (PDTs), today announced the company will
participate in Citi’s 17th Annual BioPharma Conference taking place
September 7-8 in Boston, Massachusetts. Yuri Maricich, MD, Chief
Medical Officer, will participate in a panel discussion on Mental
Health at 10:30 a.m. ET on Wednesday, September 7.
Pear will be available for one-on-one meetings during the
conference. Investors interested in meeting with Pear at the
conference should contact their Citi representative.
A live audio webcast of the presentation can be accessed by
clicking here and will be made available in the Investors section
of Pear’s website at www.peartherapeutics.com. A replay of the
webcast will be available on Pear’s website for up to 30 days
following the live presentation.
About Pear Therapeutics
Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is
the parent company of Pear Therapeutics (US), Inc. Pear is the
leader in developing and commercializing software-based medicines,
called prescription digital therapeutics (PDTs). Pear aims to
redefine care through the widespread use of clinically validated
software-based therapeutics to provide better outcomes for
patients, smarter engagement and tracking tools for clinicians, and
cost-effective solutions for payers. Pear has the first end-to-end
platform to discover, develop, and deliver PDTs to patients and a
pipeline of products and product candidates across therapeutic
areas., including the first three PDTs with disease treatment
claims from the FDA. Pear’s product, reSET®, for the treatment of
substance use disorder, was the first PDT to receive marketing
authorization from the FDA to treat disease. Pear’s second product,
reSET-O®, for the treatment of opioid use disorder, was the first
PDT to receive Breakthrough Designation. Pear’s third product,
Somryst® for the treatment of chronic insomnia, was the first PDT
submitted through FDA’s traditional 510(k) pathway while
simultaneously reviewed through FDA’s Software Precertification
Pilot Program. For more information, visit Pear at
www.peartherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220831005067/en/
Media and Investors: Meara Murphy Senior Director,
Corporate Communications meara.murphy@peartherapeutics.com
Pear Therapeutics (NASDAQ:PEAR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pear Therapeutics (NASDAQ:PEAR)
Historical Stock Chart
From Jul 2023 to Jul 2024